[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571027":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":37,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group",null,"sintilimab + fruquintinib",[13],"Other: treatment option-sintilimab plus fruquintinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group","fruquintinib",[18],"Other: treatment option-fruquintinib alone",[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"treatment option-sintilimab plus fruquintinib","sintilimab plus fruquintinib",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"treatment option-fruquintinib alone","fruquintinib alone",[15],[29],{"name":30,"affiliation":5,"role":31},"Nan Zhang","STUDY_DIRECTOR",[33],{"name":30,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","18686440802","zhangnan@jlu.edu.cn",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Changchun","Jilin","130021","China","CN",{"type":46,"coordinates":47},"Point",[48,49],125.32278,43.88,{"lat":49,"lon":48},[52],{"name":30,"role":34,"phone":53,"phoneExt":10,"email":36},"+8618686440802",{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571027","effect-of-gut-microbiota-and-its-metabolites-on-the-efficacy-of-immunotherapy-in-metastatic-colorectal-cancer-100571027",false,"NCT06714903","Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer","Multi-omics Study of Intestinal Microecology in Patients with Colorectal Cancer Related to Immunotherapy","Inclusion Criteria:\n\n* Clinical and pathological diagnosis of metastatic colorectal cancer\n* 35-75 years old (both ends inclusive)\n* complete clinical information\n* signed informed consent\n\nExclusion Criteria:\n\n* combined with severe respiratory and circulatory diseases\n* combined with other malignant tumors\n* recent severe active bleeding, uncontrolled active infection or active peptic ulcer\n* moderate to severe renal insufficiency\n* other circumstances that are judged by the investigator to be unsuitable for participating in this study","ALL","35 Years","75 Years",{"count":67,"type":68},50,"ESTIMATED","6 Months","OBSERVATIONAL","The purpose of this observational study is to understand the effect of gut microbiota on the efficacy of immunotherapy in patients with metastatic colorectal cancer and to explore the specific mechanisms of this process. In this way, it provides new ideas for the clinical treatment of colorectal cancer.",[73],"Colorectal Neoplasms Malignant",[75,76,77,78,79],"Metastatic colorectal cancer","Immunotherapy","Gut microbiota","Prognosis","Metabolism","2024-12-02",{"date":82,"type":83},"2024-12-04","ACTUAL",{"date":85,"type":83},"2024-07-15",{"date":87,"type":68},"2025-12-31",{"name":5,"class":6},1]